Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Reteplase. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Reteplase. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Reteplase. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Reteplase is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Reteplase. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Reteplase. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Obinutuzumab. |
| Rivaroxaban | Reteplase may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Reteplase is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Reteplase. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Reteplase. |
| Urokinase | Urokinase may increase the anticoagulant activities of Reteplase. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Reteplase. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Reteplase. |
| Aprotinin | The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Reteplase. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Reteplase. |
| Quinine | The therapeutic efficacy of Reteplase can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Reteplase can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Reteplase. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Reteplase. |
| Pentoxifylline | The therapeutic efficacy of Reteplase can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Reteplase. |
| Levocarnitine | The therapeutic efficacy of Reteplase can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Reteplase. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Reteplase. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Reteplase. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Reteplase. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Reteplase. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Reteplase. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Reteplase. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Reteplase. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Reteplase. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Reteplase. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Reteplase. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Reteplase. |
| Equol | Equol may decrease the anticoagulant activities of Reteplase. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Reteplase. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Reteplase. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Reteplase. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Reteplase. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Reteplase. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Reteplase. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Reteplase. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Reteplase. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Reteplase. |
| Estriol | Estriol may decrease the anticoagulant activities of Reteplase. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Reteplase. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Reteplase. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Reteplase. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Reteplase. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Reteplase. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Reteplase. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Reteplase. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Reteplase. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Reteplase. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Reteplase. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Reteplase. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Reteplase. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Reteplase. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Reteplase. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Reteplase. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Reteplase. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Reteplase. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Reteplase. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Reteplase. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Reteplase. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Reteplase. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Reteplase. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Reteplase. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Reteplase. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Reteplase. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Reteplase. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Reteplase. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Reteplase. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Reteplase. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Reteplase. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Reteplase. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Reteplase. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Reteplase. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Reteplase. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Reteplase. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Reteplase. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Reteplase. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Reteplase. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Reteplase. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Reteplase. |